Comparing tau status determined via plasma pTau181, pTau231 and [¹⁸F]MK6240 tau-PET.

ABSTRACT:

Background

Tau in Alzheimer's disease (AD) is assessed via cerebrospinal fluid (CSF) and Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in blood have been recently developed. We aim to investigate agreement of tau status as determined by [¹⁸F]MK6240 tau-PET, plasma pTau181 and pTau231.

Methods

We assessed cognitively unimpaired young, cognitively unimpaired, mild cognitive impairment and AD individuals with [¹⁸F]MK6240, plasma pTau181, pTau 231, [¹⁸F]AZD4694 amyloid-PET and MRI. A subset underwent CSF assessment. We conducted ROC curves to obtain cut-off values for plasma pTau epitopes. Individuals were categorized as positive or negative in all biomarkers. We then compared the distribution among concord

SUBMITTER: Tissot C 

PROVIDER: S-EPMC8844756 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature